Sustained delivery system intended to ease AMD treatment burden

A new port delivery system may secure sustained, long-term release of anti-VEGF in patients with wet age-related macular degeneration, easing the burden of repeated injections. The implantable device was recently tested in a phase 2 trial with positive outcomes.
“The results of the LADDER (Long Acting Delivery of Ranibizumab) trial exceeded expectations in terms of durability. We are very excited and believe that this device will be a nice potential alternative to regular, frequent injections for patients and doctors,” study investigator Carl D. Regillo, MD, said.
The ranibizumab

Full Story →